CA3201612A1 - Combination therapies for the treatment of cancer - Google Patents

Combination therapies for the treatment of cancer Download PDF

Info

Publication number
CA3201612A1
CA3201612A1 CA3201612A CA3201612A CA3201612A1 CA 3201612 A1 CA3201612 A1 CA 3201612A1 CA 3201612 A CA3201612 A CA 3201612A CA 3201612 A CA3201612 A CA 3201612A CA 3201612 A1 CA3201612 A1 CA 3201612A1
Authority
CA
Canada
Prior art keywords
compound
formula
cancer
kras
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3201612A
Other languages
English (en)
French (fr)
Inventor
Leenus MARTIN
Leslie Harris BRAIL
Robert Field SHOEMAKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasca Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3201612A1 publication Critical patent/CA3201612A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3201612A 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer Pending CA3201612A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063124669P 2020-12-11 2020-12-11
US63/124,669 2020-12-11
US202163214736P 2021-06-24 2021-06-24
US63/214,736 2021-06-24
US202163277555P 2021-11-09 2021-11-09
US63/277,555 2021-11-09
US202163283035P 2021-11-24 2021-11-24
US63/283,035 2021-11-24
PCT/US2021/062927 WO2022125971A1 (en) 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3201612A1 true CA3201612A1 (en) 2022-06-16

Family

ID=81974015

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3201612A Pending CA3201612A1 (en) 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer

Country Status (7)

Country Link
US (1) US20250195533A1 (enExample)
EP (1) EP4259639A4 (enExample)
JP (1) JP2023553534A (enExample)
KR (1) KR20230151981A (enExample)
AU (1) AU2021397319A1 (enExample)
CA (1) CA3201612A1 (enExample)
WO (1) WO2022125971A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240374525A1 (en) * 2022-08-19 2024-11-14 Mirati Therapeutics, Inc. Adagrasib solid pharmaceutical compositions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
TW202322809A (zh) * 2021-10-06 2023-06-16 美商艾瑞斯卡公司 三取代雜芳基衍生物作為src同源-2磷酸酶抑制劑之用途
EP4426303B1 (en) * 2021-11-02 2025-10-08 Semmelweis Egyetem Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014206344A1 (en) * 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
UA127968C2 (uk) * 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
JP7337174B2 (ja) * 2018-09-18 2023-09-01 ニカング セラピューティクス， インコーポレイテッド Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
US12377101B2 (en) * 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
CN113382774A (zh) * 2019-02-12 2021-09-10 诺华股份有限公司 包含tno155和krasg12c抑制剂的药物组合
EP4259147A4 (en) * 2020-12-11 2024-10-23 Erasca, Inc. Combination therapies for the treatment of cancer
KR20230152652A (ko) * 2020-12-11 2023-11-03 에라스카, 아이엔씨. 암 치료를 위한 병용 요법
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240374525A1 (en) * 2022-08-19 2024-11-14 Mirati Therapeutics, Inc. Adagrasib solid pharmaceutical compositions
US12383503B2 (en) 2022-08-19 2025-08-12 Mirati Therapeutics, Inc. Adagrasib solid pharmaceutical compositions
US12653789B2 (en) * 2022-08-19 2026-06-16 Mirati Therapeutics, Inc. Adagrasib solid pharmaceutical compositions
EP4572753A4 (en) * 2022-08-19 2026-07-22 Mirati Therapeutics Inc SOLID PHARMACEUTICAL COMPOSITIONS OF ADAGRASIB

Also Published As

Publication number Publication date
AU2021397319A1 (en) 2023-07-27
WO2022125971A1 (en) 2022-06-16
AU2021397319A9 (en) 2024-05-16
KR20230151981A (ko) 2023-11-02
EP4259639A1 (en) 2023-10-18
JP2023553534A (ja) 2023-12-21
EP4259639A4 (en) 2024-10-23
US20250195533A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
US20240293422A1 (en) Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
US20250195533A1 (en) Combination therapies for the treatment of cancer
US20240050441A1 (en) Combination therapies for the treatment of cancer
EP2205242B1 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US20170196878A1 (en) Use of cbp/ep300 and bet inhibitors for treatment of cancer
US20240058352A1 (en) Combination therapies for the treatment of cancer
AU2014331697A1 (en) Use of CBP/EP300 bromodomain inhibitors for cancer immunotherapy
US20240285624A1 (en) Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
TW202409075A (zh) 用莫蘇妥珠單抗及來那度胺治療先前未經治療的濾泡性淋巴瘤之方法
CN117098537A (zh) 用于癌症治疗的联合疗法
WO2023059771A1 (en) Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
WO2025226830A1 (en) Shp2 and egfr inhibitors for the treatment of chordoma
HK40103172A (en) Combination therapies for the treatment of cancer
CN117120449A (zh) 用于癌症治疗的联合疗法
HK40103380A (en) Combination therapies for the treatment of cancer
HK40103377A (zh) 用於癌症治疗的联合疗法
US20220304972A1 (en) Combination therapy and biomarker indicating efficacy thereof
CN117083283A (zh) 用于癌症治疗的联合疗法
TW202348626A (zh) 用莫蘇妥珠單抗及來那度胺治療復發性／難治性濾泡性淋巴瘤之方法
HK1145287B (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241125

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241125

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251023

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260430